前天是美國臨床腫瘤學(xué)會(huì)（ASCO）年會(huì)的最后一天,。該組織的年會(huì)也是全世界規(guī)模最大的癌癥會(huì)議,，吸引了超過3萬名腫瘤學(xué)研究人員、生物制藥公司高管,、投資人和公共健康專家參加,。

美國腫瘤學(xué)會(huì)為大大小小的生物科技和制藥公司提供了一個(gè)展示各種現(xiàn)有和實(shí)驗(yàn)性藥物的最新臨床試驗(yàn)數(shù)據(jù)的機(jī)會(huì)。年會(huì)期間,，還舉辦了幾個(gè)專門用來討論藥品定價(jià)及醫(yī)學(xué)標(biāo)準(zhǔn)等政策問題的論壇,。去年，美國前副總統(tǒng)拜登在年會(huì)上做主題演講時(shí),，還宣布聯(lián)邦政府將制定一項(xiàng)基因數(shù)據(jù)共享計(jì)劃,，以促進(jìn)癌癥研究。

那么,，今年的ASCO年會(huì)又給我們帶來了癌癥研究方面的哪些新進(jìn)展呢,？

小公司憑借出色成績成為焦點(diǎn)

在2017年的ASCO年會(huì)上，有好幾項(xiàng)癌癥研究方面的最新進(jìn)展都來自一些相對較小的公司,，比如斯坦福市的Loxo Oncology公司,，中國的南京傳奇生物技術(shù)公司等等。在中期試驗(yàn)中,，Loxo Oncology公司主打的試驗(yàn)性抗癌藥物larotrectinib對體內(nèi)帶有一種特定基因標(biāo)記的病人中的76%都產(chǎn)生了較好的療效,，而該公司的股票也飆升了近50%。也就是說,，只要病人身上帶有這種基因標(biāo)記,，這種藥物就會(huì)對病人患上的多種癌癥有效。而南京傳奇生物技術(shù)公司則為我們展示了一種抗癌新療法的早期數(shù)據(jù)（這種療法又叫CAR-T免疫療法,，通過對病人免疫細(xì)胞的重新編程來對抗血癌）,。從數(shù)據(jù)來看,，這家公司完全有與諾華制藥,、凱特制藥公司（Kite Pharma）、朱諾治療公司（Juno Therapeutics）等同領(lǐng)域的制藥或生物科技巨頭一較高下的能力,。南京傳奇生物技術(shù)公司的產(chǎn)品瞄準(zhǔn)了另一種生物標(biāo)記,，現(xiàn)在它正在針對多發(fā)性骨骼瘤進(jìn)行測試——這也是一種較為罕見的血癌。

輝瑞140億美元收購Medivation被批報(bào)價(jià)報(bào)高

去年夏天,，輝瑞制藥以140億美元收購了癌癥生物科技公司Medivation,，當(dāng)時(shí)所有人都覺得輝瑞是這筆生意的大贏家。當(dāng)時(shí)輝瑞的報(bào)價(jià)比Medivation公司的市值還要高出20%，但是很多藥企都看上了該公司研發(fā)的前列腺癌藥物恩雜魯胺（Xtandi）,，紛紛向該公司伸出橄欖枝,，其中最有名的一家潛在買主就是法國的賽諾菲。不過輝瑞在本次ASCO年會(huì)上展示的數(shù)據(jù)讓有些分析師表示,，輝瑞當(dāng)初給出的報(bào)價(jià)可能過高了,。因?yàn)閺?qiáng)生公司自家研發(fā)的抗癌藥物阿比特龍（Zytiga）的臨床效果非常喜人，很多投資者和醫(yī)生都認(rèn)為,，阿比特龍將成為前列腺患者的首選藥物,。在臨床試驗(yàn)中，阿比特龍使患者的死亡風(fēng)險(xiǎn)降低了38%,，這意味著用不了多久,，醫(yī)生們就會(huì)在病人患病的早期階段給他們開出這種藥物。雖然恩雜魯胺的出現(xiàn)搶占了阿比特龍的部分市場份額,，但這種趨勢可能很快就會(huì)自行扭轉(zhuǎn)回來,。

聯(lián)合用藥將成未來趨勢，且有可能加速制藥企業(yè)的合并

當(dāng)前腫瘤研究的最大趨勢之一,，就是研究將新一代的癌癥免疫療法——免疫檢查點(diǎn)抑制劑（如默克公司的默沙東,、百時(shí)美施貴寶公司的Opdivo等）與其它癌癥療法進(jìn)行組合，從而使治療變得更有效力,，以幫助更多的病人,。目前各大藥廠針對這種雞尾酒療法已經(jīng)開展了大量臨床研究，這種療法一般以一種免疫檢查點(diǎn)抑制劑為核心,，再加上另一種不同的抗癌療法,。生物科技界投資人、一家癌癥免疫基金的經(jīng)理布拉德?倫卡爾在采訪中對《財(cái)富》表示,，這種趨勢很可能會(huì)促進(jìn)癌癥研究界的進(jìn)一步融合,。“在我看來,，這是一個(gè)符合邏輯的趨勢,。”為了進(jìn)一步發(fā)揮現(xiàn)有藥物的效能以及提高銷量,，很多大型制藥公司可能會(huì)被迫吃進(jìn)更多資產(chǎn),，從而掀起一波收并購的熱潮。（財(cái)富中文網(wǎng)）

譯者：樸成奎

Today is the last day of the annual American Society of Clinical Oncology (ASCO) meeting in Chicago. The yearly confab is the biggest cancer conference in the world, attracting more than 30,000 oncology researchers, biopharma executives, investors, and public health experts.

ASCO presents tiny biotechs and drug giants alike an opportunity to present their latest clinical trial data for both old and experimental drugs. There are also forums dedicated to policy issues such as drug pricing and medical standards—last year, former Vice President Joe Biden announced a federal Genomic Data Commons to expedite cancer research during a keynote address.

Here are some of the key stories to come out of this year's meeting.

Smaller companies grab the spotlight with impressive early results.

Several of the biggest headlines to come out of ASCO 2017 involve relatively small companies like Stamford, CT-based Loxo Oncology and China's Nanjing Legend Biotech. The former saw its stock price soar nearly 50% after unveiling that its lead experimental drug, larotrectinib, produced a response in 76% of patients with a specific kind of genetic marker in a mid-stage trial. That means that the drug could prove effective in a variety of cancers so long as patients have that marker. Nanjing Legend, meanwhile, presented early data on a new kind of cancer treatment (CAR-T, which involves re-engineering patients' immune cells to fight blood cancers) that could help pit the company against drug giants like Novartis and biotechs like Kite Pharma and Juno Therapeutics which are also working in the field. Nanjing's product targets a different kind of biomarker and is being tested in multiple myeloma, a rare blood cancer.

Pfizer's $14 billion Medivation deal comes under scrutiny.

Pfizer was considered a major winner when it snapped up cancer biotech Medivation for $14 billion last summer. That offer (a 20% premium over the firm's market value at the time) came after a frenzy of drug makers tried to land the firm and its prostate cancer treatment Xtandi, most notably France's Sanofi. But new data presented at ASCO has some analysts wondering if Pfizer overpaid. That's because Johnson & Johnson's own therapy Zytiga produced clinical results so impressive that some investors and doctors are already predicting it will become a go-to option for newly-diagnosed men with high-risk prostate cancer. Consider: Zytiga cut the death risk for patients by 38% in a trial, meaning it could soon be prescribed much earlier in the treatment process. The J&J drug had been ceding some market share to Xtandi; that trend could very well reverse itself now.

Drug combinations are the wave of the future—and could accelerate biopharma deals.

One of the biggest trends in oncology R&D is testing out combinations of next-generation cancer immunotherapies called "checkpoint inhibitors" (such as Merck's Keytruda and Bristol-Myers Squibb's Opdivo) with other cancer treatments in order to make combos which could prove more effective and help a wider swath of patients. There are mountains of clinical studies testing these kinds of drug cocktails, often featuring a backbone checkpoint inhibitor drug in addition to a different type of therapy from a cancer-focused biotech. And that could very well lead to even more consolidation in the oncology sphere, biotech investor and immuno-oncology fund manager Brad Loncar tells Fortune in an interview. "That seems like a logical trend to me," he said, since bigger drug companies will likely feel compelled to snatch up assets that could make their existing medicines more effective (and rake in more sales).